Review on elipse intra-gastric balloon
Journal name: World Journal of Pharmaceutical Research
Original article title: Review on elipse intra-gastric balloon
The WJPR includes peer-reviewed publications such as scientific research papers, reports, review articles, company news, thesis reports and case studies in areas of Biology, Pharmaceutical industries and Chemical technology while incorporating ancient fields of knowledge such combining Ayurveda with scientific data.
This page presents a generated summary with additional references; See source (below) for actual content.
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
Vaishnavi Dasari, Akarapu Thanmaya Lakshmi, L. Sarveshwar Goud, A. Santosh Yadav and K. Amuktha Malyada
World Journal of Pharmaceutical Research:
(An ISO 9001:2015 Certified International Journal)
Full text available for: Review on elipse intra-gastric balloon
Source type: An International Peer Reviewed Journal for Pharmaceutical and Medical and Scientific Research
Doi: 10.20959/wjpr20222-22878
Copyright (license): WJPR: All rights reserved
Download the PDF file of the original publication
Summary of article contents:
Introduction
The Elipse Intra-Gastric Balloon is a groundbreaking, non-surgical method for treating obesity, recently approved by the Food and Drug Administration (FDA). This innovative approach provides an alternative to traditional weight loss surgeries by employing an inflatable medical device that can be inserted into the stomach without the need for endoscopy or anesthesia. The Elipse balloon, administered during a quick outpatient visit, effectively aids patients in weight loss, marking it as a significant advancement in obesity treatment.
Non-Surgical Weight Loss
The Elipse balloon is unique as it can be swallowed like a pill and subsequently expands into a fluid-filled balloon within the stomach. This balloon, filled with 450 ml of saline, occupies space in the stomach, helping to reduce hunger and promote early satiety. After a deployment period of six weeks, the balloon is designed to deflate and pass naturally through the gastrointestinal tract. As a result, patients can experience substantial weight loss—ranging from 10 to 15 kilograms—without undergoing extensive lifestyle changes involving strict diets or exercise regimens.
Study Insights
A multicenter study investigating the Elipse Intra-Gastric Balloon involved patients who underwent balloon insertion and were tracked over a 16-week period. Their weight, body mass index, and any adverse effects were documented. Remarkably, 69.6% of the patients experienced complete resolution of their symptoms by the third day. While most patients reported mild nausea during balloon insertion, the procedure itself was deemed safe, with no major complications occurring. A small percentage reported early deflation or discomfort during the balloon's presence, suggesting that while side effects are common, serious issues are rare.
Quality of Life Improvement
The deployment of the Elipse balloon also correlates with noticeable improvements beyond just weight loss. Patients reported enhancements in waist circumference and overall metabolic health. This method serves not only as a tool for physical change but also contributes positively to the patients' quality of life throughout the duration of the six-month program. The ease and effectiveness of this procedure mark a pivotal step forward in obesity treatment strategies, clearly demonstrating its potential to improve the wellbeing of individuals struggling with weight management.
Conclusion
In summary, the Elipse Intra-Gastric Balloon represents an exciting development in the field of weight loss and obesity management. Through non-invasive means, it provides a feasible option for those seeking to lose weight and enhance their overall health. The positive results and safety profile observed in studies advocate for its integration into weight management programs. As ongoing research further elucidates its benefits, the Elipse balloon could play a critical role in addressing obesity, ultimately contributing to improved health outcomes for many individuals.
FAQ section (important questions/answers):
What is the Elipse Intra-Gastric Balloon and its purpose?
The Elipse Intra-Gastric Balloon is a non-surgical medical device designed for effective weight loss. It is approved by the FDA and is inserted endoscopically into the stomach to help manage obesity.
How does the Elipse balloon differ from traditional gastric balloons?
Unlike traditional gastric balloons, the Elipse balloon requires no surgery, endoscopy, or anesthesia for insertion or removal. Patients swallow a capsule that expands into a balloon filled with saline.
What is the procedure duration for the Elipse balloon insertion?
The insertion of the Elipse balloon takes approximately 15 minutes as an outpatient procedure, allowing patients to return home within an hour after the insertion.
What kind of weight loss results can be expected?
Patients can expect to lose between 10-15 kg over the 6-month program duration, leading to improvements in their waist circumference and overall quality of life without strict diets or exercises.
What complications can occur during or after the Elipse procedure?
Most patients report mild nausea after insertion. Some experience vomiting, early deflation, diarrhea, or abdominal pain. Serious complications are rare, and any issue can be addressed with a laparoscopic procedure if necessary.
How long does the Elipse balloon remain in the stomach?
The Elipse balloon typically remains in the stomach for about 6 months before being excreted naturally through the stool after it deflates.
Glossary definitions and references:
Scientific and Ayurvedic Glossary list for “Review on elipse intra-gastric balloon”. This list explains important keywords that occur in this article and links it to the glossary for a better understanding of that concept in the context of Ayurveda and other topics.
1) Dasari:
Dasari refers to Vaishnavi Dasari, one of the primary authors of the study on the Elipse Intra-Gastric Balloon. Her academic affiliation indicates her involvement in research, contributing to the understanding and evaluation of non-surgical weight loss methods. Dasari's research accentuates the significance of innovative medical devices in treating obesity.
2) Filling (Filled):
The term 'filled' describes the process by which the Elipse Intra-Gastric Balloon is administered. It is filled with saline to create a physical obstruction in the stomach, promoting a feeling of satiety. This mechanism is crucial for its function as a non-surgical weight loss solution.
3) India:
India is the geographical context where the research was conducted, specifically at institutions like Bhaskar Pharmacy College and Malla Reddy College of Pharmacy. The region’s healthcare challenges, particularly related to obesity, underscore the importance of innovative treatments like the Elipse balloon, contributing to global medical advancements.
4) Vaishnavi (Vaisnavi):
Vaishnavi refers to Vaishnavi Dasari, the lead author of the research article. She plays a pivotal role in the study's formulation and execution, emphasizing the academic contribution of young researchers in advancing healthcare practices related to obesity and non-invasive medical solutions.
5) Swallowed:
The term 'swallowed' pertains to the method of administering the Elipse Intra-Gastric Balloon, emphasizing its non-invasive nature. Patients can ingest the balloon in a pill form, which then expands in the stomach. This process highlights a significant advancement in gastroenterology and bariatric treatments.
6) Malla:
Malla refers to Malla Reddy College of Pharmacy, the institution affiliated with several authors of the research. This college plays an integral role in pharmaceutical education and research initiatives within India, contributing to the field of therapeutic advancements in the treatment of obesity through innovative methods.
7) Diet:
Diet is a critical factor in the context of the Elipse Intra-Gastric Balloon study. The research notes that patients did not follow a specific diet or exercise regimen during the observation period. The balloon’s effectiveness in promoting weight loss without dietary restrictions is a significant finding.
8) Performance:
Performance refers to the effectiveness and outcomes of the Elipse Intra-Gastric Balloon as evaluated in the study. This encompasses weight loss results and the safety profile observed during the clinical trials, highlighting the device's role in providing a viable alternative for obesity management.
9) Observation:
Observation pertains to the monitoring of patients after the insertion of the Elipse Intra-Gastric Balloon. Regular assessments help document weight loss, BMI, and any adverse effects, providing valuable data regarding the balloon's impact and reinforcing the importance of systematic clinical evaluations.
10) Lakshmi (Laksmi):
Lakshmi refers to Akarapu Thanmaya Lakshmi, one of the co-authors of the research. Her involvement signifies collaborative academic efforts in studying modern medical devices. Researchers like Lakshmi contribute to interdisciplinary approaches in addressing obesity through innovative, less invasive procedures.
11) Quality:
Quality refers to the improvement in the patients' overall quality of life resulting from the Elipse therapy. The study assesses not only the physical outcomes, like weight loss but also the psychological and social dimensions, emphasizing the holistic benefits of such medical interventions in obesity treatment.
12) Account:
Account here relates to the documentations and records maintained throughout the study, encompassing patient experiences, weight loss statistics, and any complications arising from the use of the Elipse balloon. Accurate accounts are essential for evaluating the device's success and informing future research.
13) Samtosha (Samtosa, Santosa, Santosh, Santosha):
Santosh refers to A. Santosh Yadav, another co-author in the study. His contributions point towards collaborative research efforts. Names like his reflect collective academic engagement aimed at addressing obesity challenges faced in contemporary medicine through innovative strategies and advanced healthcare solutions.
14) Nausea:
Nausea is one of the common side effects experienced by patients during the initial stages post-insertion of the Elipse balloon. Its occurrence indicates the physiological adjustments the body undergoes with the introduction of the balloon, making it a vital observation in evaluating patient experiences.
15) Visit:
Visit denotes the brief outpatient appointment for the balloon's insertion, where patients undergo the procedure in about 15 minutes. This highlights the efficiency and non-invasive nature of the Elipse procedure, providing a critical advantage for patient convenience in obesity treatment.
16) Matam:
Madam refers to Ms. K. Manga, who is acknowledged for guiding and promoting the review article. Her mentorship illustrates the importance of academic guidance in research, providing support that can enhance the quality and reach of scholarly work in the pharmaceutical field.
17) Goud:
Goud refers to L. Sarveshwar Goud, another contributor to the research article. Individuals like Goud play a significant role in collaborative research initiatives, enriching the study with diverse perspectives and expertise, which is essential for multidimensional approaches to medical challenges, such as obesity.
18) Food:
Food is indirectly relevant as it relates to the dietary habits and preferences of patients undergoing Elipse therapy. Understanding dietary influences is crucial for contextualizing the treatment's effectiveness in weight loss, given the absence of prescribed diets in the studied cohort.
19) Pain:
Pain is a symptom experienced by some patients during the deflation of the Elipse balloon. Documenting pain levels is essential for assessing the device's overall safety and patient comfort, influencing future medical practices regarding the use of gastric balloons for weight management.
20) Drug:
Drug refers to the broader category of pharmacological agents that may be involved in weight management, contrasting with the non-surgical approach of the Elipse balloon. Awareness of drug alternatives highlights the diversity of treatment modalities available for obesity, emphasizing the need for comprehensive therapeutic options.
21) Life:
Life pertains to the overall quality of life improvements noted among patients receiving Elipse therapy. Evaluating quality of life is an essential component of healthcare outcomes, reflecting the broader impacts of medical interventions beyond mere physical health, especially in chronic conditions like obesity.
Other Science Concepts:
Discover the significance of concepts within the article: ‘Review on elipse intra-gastric balloon’. Further sources in the context of Science might help you critically compare this page with similair documents:
Abdominal pain, Adverse effect, Non-surgical treatment, Quality of life, Sample size, Body mass index, Food and Drug Administration, Weight loss, Lifestyle program.